CD36 and cancer: Thus, in addition to perturbing tumor growth, metastasis, and drug resistance via targeting CD36 in cancer cells, the concurrent inhibition of CD36 on intratumoral Tregs, CD8+ T cells, and M2 TAMs would offer the additional bonus of eliciting anti-tumor immunity to further reduce the tumor burden (Figure 4).